Real-world outcomes for multiple myeloma patients after apheresis for planned chimeric antigen receptor T-cell therapy

Figure 2 Kaplan-Meier estimates of overall survival from the date of apheresis in patients with relapsed/refractory multiple myeloma who underwent T-cell collection for planned B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy (n = 99). Line definitions: The blue line denotes patients who proceeded to chimeric antigen receptor T-cell infusion (infused cohort, n = 87). The purple line denotes patients who underwent apheresis but never received an infusion (non-infused cohort, n = 12). Overall survival was measured from the date of apheresis (day 0, index date) to death from any cause; patients alive at last contact were censored at the date of last follow-up (data cut-off 12 July 2024). Vertical tick marks indicate censored observations; the shaded bands, where shown, represent 95% confidence intervals; the table beneath the x-axis reports the number of patients at risk in each group at each 3-month interval. Median overall survival was not reached in the infused cohort and 1.9 months in the non-infused cohort. The X-axis shows time in months from apheresis and should be extended to the maximum observed follow-up; the Y-axis shows the estimated probability of overall survival. OS: Overall survival.